| Literature DB >> 36112262 |
Ricardo Alva1, Maha Mirza1, Adam Baiton1, Lucas Lazuran1, Lyuda Samokysh1, Ava Bobinski1, Cale Cowan1, Alvin Jaimon1, Dede Obioru1, Tala Al Makhoul1, Jeffrey A Stuart2.
Abstract
In clinical settings, oxygen therapy is administered to preterm neonates and to adults with acute and chronic conditions such as COVID-19, pulmonary fibrosis, sepsis, cardiac arrest, carbon monoxide poisoning, and acute heart failure. In non-clinical settings, divers and astronauts may also receive supplemental oxygen. In addition, under current standard cell culture practices, cells are maintained in atmospheric oxygen, which is several times higher than what most cells experience in vivo. In all the above scenarios, the elevated oxygen levels (hyperoxia) can lead to increased production of reactive oxygen species from mitochondria, NADPH oxidases, and other sources. This can cause cell dysfunction or death. Acute hyperoxia injury impairs various cellular functions, manifesting ultimately as physiological deficits. Chronic hyperoxia, particularly in the neonate, can disrupt development, leading to permanent deficiencies. In this review, we discuss the cellular activities and pathways affected by hyperoxia, as well as strategies that have been developed to ameliorate injury. • Hyperoxia promotes overproduction of reactive oxygen species (ROS). • Hyperoxia dysregulates a variety of signaling pathways, such as the Nrf2, NF-κB and MAPK pathways. • Hyperoxia causes cell death by multiple pathways. • Antioxidants, particularly, mitochondria-targeted antioxidants, have shown promising results as therapeutic agents against oxygen toxicity in animal models.Entities:
Keywords: Antioxidants; Cell death; Hyperoxia; Mitochondria; Oxygen toxicity; Reactive oxygen species
Year: 2022 PMID: 36112262 PMCID: PMC9483325 DOI: 10.1007/s10565-022-09773-7
Source DB: PubMed Journal: Cell Biol Toxicol ISSN: 0742-2091 Impact factor: 6.819
Fig. 1Signaling pathways affected in hyperoxia. Excessive ROS modulate intracellular signaling, including via nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and mitogen-activated protein kinase (MAPK) pathways. In parallel, oxidative damage to DNA activates p53, which induces the transcription of target genes. In turn, damage-associated molecular patterns (DAMPs) upregulated by these pathways are released into the extracellular space, where they can bind receptors such as the toll-like receptor 4 (TLR4) and further activate the NF-κB pathway. Signaling events orchestrated by these and other pathways determine the outcome of hyperoxia-mediated oxidative stress and may include cell survival, senescence, death, and inflammation. Created with BioRender.com
Fig. 2Mitochondrial targets of hyperoxia-mediated injury. Hyperoxia drives the over production of mitochondrial reactive oxygen species (ROS), which inhibit metabolic enzymes such as aconitase, α-ketoglutarate dehydrogenase (α-KGDH), and pyruvate dehydrogenase (PDH), and respiratory complexes I and II, leading to bioenergetic failure. mROS oxidize mitochondrial DNA (mtDNA) and cardiolipin (CL), further promoting dysfunction and leading to the release of cytochrome c (cyt c) into the cytosol through Bcl-2-associated X protein/Bcl-2 homologous antagonist killer (Bax/Bak) oligomers to instigate apoptosis. Created with BioRender.com
Evidence of the roles of noncoding RNA molecules in hyperoxia
| RNA molecule | Type of RNA | Hyperoxic model | Outcome | Reference |
|---|---|---|---|---|
| miR-150 | miRNA | Lung injury/newborn mice/95% O2/3–10 days | • Downregulated in hyperoxia • KO decreased lung injury | (Narasaraju et al. |
| Lung injury/primary mouse lung epithelial cells, BEAS-2B and A549 cells/95% O2/12–72 h | • Cytoprotective effect | (Zhang et al. | ||
| miR-876-3p | miRNA | Lung injury/newborn mice/85–100% O2/4–14 days Normal human bronchial epithelial/85% O2/24 h | • Downregulated in hyperoxia • Predicted protective effect against injury | (Lal et al. |
| miR-16 | miRNA | Lung injury/isolated T2AECs/60% O2 /24 h | • Downregulated in hyperoxia • miR-16 mimics inhibited apoptosis and the TGF‐β/Smad2 and Jak/STAT3 pathways | (Li et al. |
| miR-34a | miRNA | Lung injury/newborn mice/100% O2/4 or 7 days Isolated T2AECs and MLE-12 cells/40–95% O2/4–48 h | • Silencing ameliorated apoptosis in vitro and in vivo • Overexpression aggravated injury | (Syed et al. |
Lung injury/newborn mice/85% O2/14 days MLg cells/85% O2/unspecified duration | • Upregulated in hyperoxia • Deletion protected against injury | (Ruiz-Camp et al. | ||
| miR-17 | miRNA | Lung injury/newborn mice/70% O2/4–14 days | • Downregulated in hyperoxia • Downregulated STAT3 • Upregulation relieved pulmonary injury | (Zhang et al. |
| Lung injury/newborn mice/85% O2/14 days | • Downregulated in hyperoxia • Downregulation was associated with lung injury | (Wang et al. | ||
| miR-185-5p | miRNA | Lung injury/mice/95% O2/24–72 h MLE-15 cells/95% O2/24–48 h | • Upregulated in hyperoxia • Upregulated RIP1 and RIP3 • Induced necroptosis and apoptosis | (Carnino et al. |
| miR-96 | miRNA | OIR/newborn rats/cycling 10–50% O2 every 24 h/14 days Retinal vaso-obliteration/newborn rats/80% O2/5 days HRMECs/80% O2/1–48 h | • Downregulated in hyperoxia • Overexpression promoted vascular repair in vivo and protected against endothelial dysfunction in vitro | (Desjarlais et al. |
| miR-101-3p | miRNA | Lung injury/newborn mice/65% O2/7–14 days | • Overexpression mitigated injury • Downregulated HMGB3 and TGF-ß1/Smad3 axis | (Yuan et al. |
| miR-18a | miRNA | Lung injury/mouse/95% O2/7 days MLE-12 cells/95% O2/12–48 h | • Downregulated in hyperoxia • Overexpression prevented pyroptosis and relieved lung injury | (Zou et al. |
| miR-29b | miRNA | Plasma from preterm infants lung injury/newborn mice/85% O2/14 days | • Downregulated in hyperoxia • Improved alveolarization and decreased expression of ECM proteins | (Durrani-Kolarik et al. |
| miR-29a | miRNA | Lung injury/newborn mice/ > 90% O2/4 days | • Upregulated in hyperoxia • Inhibition alleviated injury | (Hu et al. |
| miR-199a-5p | miRNA | Lung injury/newborn mice/100% O2/7 days Mouse MLE-12 cells and RAW264.70 cells/95% O2/4–24 h | • Upregulated in hyperoxia • Mimic treatment worsened injury | (Alam et al. |
| miR-20b | miRNA | Lung injury/rats/95% O2/48 h | • Downregulated in hyperoxia • Overexpression downregulated Mfn1/2 and reduced apoptosis | (Mu et al. |
| miR-214 | miRNA | Lung injury/newborn rats/95% O2/7 days Alveolar epithelial cells/85% O2/24 h | • Downregulated in hyperoxia • Overexpression restored alveolarization in vivo and decreased apoptosis in vitro | (Zhang et al. |
| miR-421 | miRNA | Lung injury/newborn mice/85% O2/7 days MLE-12 cells/85% O2/6 h | • Upregulated in hyperoxia • Downregulation was associated with alleviated injury • Mimic treatment abrogated Rian-mediated protection | (Tao et al. |
| miR-194-5p | miRNA | Lung injury/newborn mice/ > 90% O2/4 days BEAS-2B cells/95% O2/48 h | • Mediated hyperoxic injury • Upregulation blocked CASC2-mediated protection | (Ji et al. |
| miR‐181c‐5p | miRNA | HLMECs/80% O2/12–24 h | • Upregulated in hyperoxia • miR‐181c‐5p mimic downregulated NCAPG and enhanced apoptosis | (Wu et al. |
| miR-342-5p | miRNA | Lung injury/newborn mice/100% O2/4–7 days T2AECs and MLE-12 cells/95% O2/2–48 h | • Downregulated in hyperoxia • Overexpression and mimic treatment ameliorated injury | (Wen et al. |
| miR-299-3p | miRNA | OIR/newborn mice/75% O2/5 days | • Downregulated in hyperoxia • Overexpression reduced apoptosis | (Wang et al. |
| FOXD3-AS1 | lncRNA | Lung injury/primary mouse lung epithelial cells, BEAS-2B and A549 cells/95% O2/12–72 h | • Upregulated in hyperoxia in vivo and in vitro • Deletion is cytoprotective in vivo and in vitro | (Zhang et al. |
| Xist | lncRNA | Lung injury/newborn mice/65% O2/7–14 days | • Upregulated in hyperoxia • Silencing protects against injury | (Yuan et al. |
| H19 | lncRNA | Lung injury/newborn mice/70% O2/4–14 days | • Upregulated in hyperoxia • Silencing upregulated miR-17, downregulated STAT3, and relieved injury | (Zhang et al. |
| MEG3 | lncRNA | Lung injury/mice/95% O2/7 days MLE-12 cells/95% O2/12–48 h | • Upregulated in hyperoxia • Knockdown inhibited NLRP3 inflammasome, caspase-1, and pyroptosis | (Zou et al. |
| MALAT1 | lncRNA | BPD patients A549 cells 92% O2/48 h | • Upregulated in BPD • Downregulated in hyperoxia in vitro • Silencing promoted apoptosis | (Zhang et al. |
| Rian | lncRNA | Lung injury/newborn mice/85% O2/7 days MLE-12 cells/85% O2/6 h | • Downregulated in vivo and in vitro • Overexpression downregulated miR-421 and alleviated injury | (Tao et al. |
| CASC2 | lncRNA | Lung injury/newborn mice/ > 90% O2/4 days/10 days recovery in normoxia BEAS-2B cells/95% O2/48 h | • Poorly expressed in hyperoxic mice • Overexpression ameliorated lung injury in vivo • Inhibited apoptosis of epithelial cells in vitro | (Ji et al. |
| DLEU2 | lncRNA | HLMECs/80% O2/12–24 h | • Downregulated in hyperoxia • Overexpression inhibited miR‐181c‐5p and hyperoxic damage | (Wu et al. |
| TUG1 | lncRNA | OIR/newborn mice/75% O2/5 days | • Upregulated in hyperoxia • Knockdown reduced pathological alterations, apoptosis, inflammation, and miR-299-3p expression | (Wang et al. |
Abbreviations: CASC2, cancer susceptibility candidate 2; DLEU2, deleted in lymphocytic leukemia 2; ECM, extracellular matrix; FOXD3-AS1, FOXD3 antisense RNA 1; HMGB3, high mobility group box 3; HLMECs, human lung microvascular endothelial cells; HPMECs, human pulmonary microvascular endothelial cells; HRMECs, human retinal microvascular endothelial cells; Jak, Janus kinase; KO, knockout; MALAT1, metastasis-associated lung adenocarcinoma transcript; MEG3, maternally expressed 3; Mfn1/2, mitofusin 1/2; NCAPG, non-SMC condensin I complex subunit G; NLRP3, NLR family pyrin domain containing 3; OIR, oxygen-induced retinopathy; RIP1/3, receptor-interacting protein 1/3; Smad2, small mothers against decapentaplegic 2; STAT3, signal transducer and activator of transcription 3; TGF-β, transforming growth factor-β; TUG1, taurine up-regulated 1; T2AECs, type II alveolar epithelial cells; Xist, X-inactive specific transcript
Therapeutic candidates studied to treat hyperoxic injury
| Candidate | Mechanism of action | Models | Outcomes | References |
|---|---|---|---|---|
| MitoTEMPO/MitoTEMPOL | Mitochondrial O2•– scavenger | Murine BPD, various in vitro models | ↑Alveolarization ↓Right ventricular hypertrophy ↓ACE2 and TMPRSS2 expression ↓Proinflammatory cytokines ↓Cell death ↓Mitochondrial fragmentation | (Datta et al. |
| Ascorbate (vitamin C) | Alkyl hydroperoxide scavenger, regenerates reduced tocopherol | Healthy patients, congestive heart failure patients, Murine HALI, various in vitro models | ↑Left ventricular function ↓Hyperventilation ↓Oxidative biomarkers in blood ↓HMGB1 levels ↓Leukocyte infiltration ↓Lipid and protein oxidation ↓Vasoconstriction | (Mak et al. |
| Tocopherol (vitamin E) | Alkyl hydroperoxide scavenger | In vitro OIR, neonatal rabbits, other in vitro models | ↓Lipid and protein oxidation ↓Vascular cell injury ↓Surfactant system impairment | (Tripathi and Tripathi |
| Retinol/retinoic acid (vitamin A) | ROS scavenger, retinoid X receptor agonist | Murine BPD | ↑Surfactant protein levels ↑Alveolar maturation ↓Lung damage ↓Growth retardation ↓MIP-2 expression | (Zimová-Herknerová et al. |
| Coenzyme Q10 | ROS scavenger | Murine neonatal organ injury | ↑Antioxidant enzyme activity in heart, kidney, and brain ↓Oxidative stress in liver | (Lee et al. |
| N-acetylcysteine | L-cysteine prodrug, replenishes GSH | Murine HALI, in vitro models | ↑Mitochondrial membrane potential ↓Lung damage ↓Cell death ↓Cyt c release ↓HGMB1 and RAGE expression ↓TLR2/4 and NF-κB activity ↓Proinflammatory cytokine secretion | (Huang et al. |
| Curcumin and analogs | ROS scavenger, multiple molecular targets | Murine BPD | ↑Relaxation of tracheal smooth muscle ↑Lung maturation ↑Alveolarization ↑PPAR-γ activation ↑Catalase activity ↓Apoptosis ↓ERK1/2 activation ↓TNF-α expression ↓TGF-β signaling | (Sakurai et al. |
| Sulforaphane | ROS scavenger, Nrf2 inducer, NF-κB inhibitor, other targets | Murine BPD and HALI | ↑Nrf2-mediated transcriptional response ↑Macrophage function ↓Inflammatory cell infiltration ↓LDH levels ↓Mucous hypersecretion | (McGrath-Morrow et al. |
| Resveratrol | ROS scavenger, SIRT1, multiple molecular targets | Murine brain injury, murine HALI and BPD | ↑SIRT1/PGC-1α signaling ↑PGC-1α, NRF1, and TFAM expression ↑Mitochondrial biogenesis ↑SOD and GSH ↓Alveolar simplification ↓Lung fibrosis ↓Apoptosis ↓Mitochondrial dysfunction ↓p53 expression ↓Proinflammatory cytokine release ↓Wnt/β-catenin signaling | (Özdemir et al. |
| Quercetin | ROS scavenger, multiple molecular targets | Murine BPD, fetal airway smooth muscle cells | ↑Alveolarization ↓Inflammation ↓NF-κB levels ↓Lipid peroxidation ↓Senescence | (Maturu et al. |
| Anthocyanins | ROS scavenger | Murine OIR, HUVECs | ↑Nrf2 gene targets ↑Cell viability ↓Mitochondrial dysmorphology ↓Endothelial cell proliferation | (Cimino et al. |
| Caffeine | ROS scavenger, A2AR antagonist, multiple molecular targets | Murine BPD, neonatal murine brain injury | ↑Alveolar development ↑Weight gain ↓DNA damage ↓A2AR expression ↓Proinflammatory cytokines ↓Inflammatory infiltration ↓Apoptosis ↓ER stress ↓NLRP3 inflammasome expression ↓NF-κB activation ↓MMP2 levels | (Endesfelder et al. |
| Indole-3-carbinol | ROS scavenger, AhR agonist/inducer, other targets | Murine BPD | ↑AhR gene targets ↑Alveolarization ↑NF-κB target genes ↓Fibrosis | (Guzmán-Navarro et al. |
| Tetrandrine | ROS scavenger, multiple molecular targets | Murine BPD | ↑Antioxidant enzymes ↓Apoptosis ↓Inflammation ↓Fibrotic markers ↓NF-κB and ERK1/2 signaling | (Jiao et al. |
| Cyclosporin A | Cyclophilin D inhibitor; delays mPTP opening | Murine | ↓Cyt c release ↓Mitochondrial swelling ↓Lung damage | (Pagano et al. |
| TRP601 | Caspase inhibitor | Murine brain injury | ↓Apoptosis ↓Neurodegeneration | (Sifringer et al. |
| Interleukin-10 | Anti-inflammatory cytokine | Murine HALI, fetal alveolar cells (in vitro) | ↑Survival ↑VEGF release ↑Proliferation ↑Jak1 and TYK2 phosphorylation ↓Lung injury ↓Cell death ↓NF-κB activation ↓Proinflammatory cytokines ↓iNOS and NO levels ↓MMP2 and MMP9 activities | (Lee and Kim |
| Interleukin-1 receptor antagonist | Anti-inflammatory cytokine | Murine BPD, murine BPD-pulmonary hypertension | ↑Pulmonary small vessels ↑Immune cell viability ↓Pulmonary vascular resistance ↓Lung structural disintegration ↓Cardiac fibrosis ↓Immune cell activation ↓Proinflammatory cytokines | (Nold et al. |
| Acetylsalicylic acid | COX inhibitor | Murine HALI | ↓NF-κB activation ↓ROS ↓Proinflammatory cytokines ↓Macrophages ↓Neutrophil infiltration ↓Lung edema | (Chen et al. |
| Ibuprofen | COX inhibitor | Murine OIR | ↓Retinopathy score ↓Extra-retinal nuclei count per section | (Sharma et al. |
| FG-4095 | PHD inhibitor | Fetal baboon lung explants, primate BPD, distinct cell lines | ↑HIF-1/2α target genes ↑Angiogenesis ↑Alveolar surface area ↑Lung compliance | (Asikainen et al. |
| Dimethyloxalylglycine | PHD inhibitor | Murine OIR | ↑Peripheral vascularity ↓Neovascularization ↓Ischemia | (Sears et al. |
| Roxadustat | PHD inhibitor | Murine BPD | ↑Survival ↑Alveolarization ↑eNOS expression ↑VEGF expression | (Huang et al. |
| Memantine | NMDA receptor antagonist | Murine brain injury | ↑Neuron viability ↓Apoptosis | (Polat et al. |
| Lacosamide | Enhances slow Na+ channel inactivation | Murine brain injury | ↑Neuron viability ↓Apoptosis | (Polat et al. |
| Vitamin D | Vitamin D receptor agonist | Murine BPD | ↑Alveolarization ↑VEGF and VEGFR2 expression ↑HIF-1α expression ↓Alveolar simplification ↓Apoptosis ↓TLR4 expression ↓IFN‐γ and IL‐1β expression ↓Neutrophil extracellular traps ↓Proinflammatory cytokines | (Kose et al. |
| Metformin | AMPK activator | Murine BPD, HUVECs | ↑Radial alveolar count ↑Vascular proliferation ↑ATP levels ↑Lung capillary number ↓Mortality ↓Inflammation ↓Fibrosis | (Chen et al. |
| Rosiglitazone | PPAR-γ agonist | Murine BPD and HALI, preterm rabbits | ↑Radial alveolar count ↑Alveolar sacculation ↑Lung maturation ↑Surfactant proteins ↑VEGF expression ↓Wnt and TGF-β signaling ↓Neutrophil influx | (Richter et al. |
| Alda-1 | ALDH2 activator | Murine HALI, HMVECs | ↑Mitochondrial membrane potential ↑Akt/mTOR signaling ↓Alveolar damage ↓Inflammation ↓Immune cell infiltration ↓Bax and cyt c levels ↓4-HNE levels | (Sidramagowda Patil et al. |
Abbreviations: ACE2, angiotensin converting enzyme 2; AhR, aryl hydrocarbon receptor; ALDH2, aldehyde dehydrogenase 2; Alda-1, ALDH2 activator 1; AMPK, adenosine monophosphate-activated kinase; ATP, adenosine triphosphate; AR, A2A adenosine receptor; BPD, bronchopulmonary dysplasia; COX, cyclooxygenase; cyt c, cytochrome c; ER, endoplasmic reticulum; ERK1/2, extracellular signal-regulated kinase 1/2; GSH, reduced glutathione; HALI, hyperoxic acute lung injury; HIF-1/2, hypoxia-inducible factor 1/2; HMGB1, high mobility group box 1; HUVECs, human umbilical vein endothelial cells; Jak, Janus kinase; IFN-γ, interferon γ; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; MIP-2, macrophage inflammatory protein 2; MMP2, matrix metalloproteinase 2; mPTP, mitochondrial permeability transition pore; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, NLR family pyrin domain containing 3; NMDA, N-methyl-D-aspartate; NRF1, nuclear respiratory factor 1; Nrf2, nuclear factor erythroid 2-related factor 2; NO, nitric oxide; eNOS, endothelial NO synthase; iNOS, inducible NO synthase; OIR, oxygen-induced retinopathy; PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator 1 α; PHD, prolyl hydroxylase domain; PPAR-γ, peroxisome proliferator-activated receptor γ; RAGE, receptor for advanced glycation end-products; ROS, reactive oxygen species; SIRT1, sirtuin 1; SOD, superoxide dismutase; TMPRSS2, transmembrane protease, serine 2; TGF-β, transforming growth factor β; TFAM, transcription factor a, mitochondrial; TLR2/4, toll-like receptor 2/4: TNF-α, tumor necrosis factor α; TYK2, tyrosine kinase 2; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2; 4-HNE, 4-Hydroxynoneal
Fig. 3Molecular mechanisms and cellular pathways of hyperoxia. Through an increased production of reactive oxygen species, hyperoxia dysregulates signaling pathways and promotes epigenetic modifications, resulting in altered gene expression, and ultimately leading to senescence, inflammation, and death. In the mitochondria, hyperoxia inhibits respiration and promotes cardiolipin oxidation and cytochrome c release, further contributing to the induction of cell death pathways. Created with BioRender.com